Feed BMY
BM

Bristol-Myers Squibb

BMY · NYSE

$63.62 -0.20% (-$0.13)
1M -0.30%
Market Cap $130.2B
P/E Ratio 14.03x
Div. Yield 3.94%
ROE 46.75%

Bulios Fair Price

$34.65

45.5% downside

Current Price

$63.62

Undervalued Fair Value Overvalued

According to Bulios Fair Price, BMY is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Strong
7/9
Valuation
78 /100
Cheap
P/FCF 11.38x
P/E 14.03x
P/B 5.83x
Growth
31 /100
Declining
FCF growth 2.44%
EPS growth 5.36%
Book val. growth 15.90%
Profitability
100 /100
Strong
Op. margin 28.27%
Gross margin 70.16%
FCF margin 23.26%
Quality
83 /100
Excellent
ROA 10.59%
ROIC 15.47%
Asset turnover 0.56x
Debt
54 /100
Moderate
Int. coverage 7.88x
Debt/Equity 1.93x
Net debt/EBITDA 2.06x
Stability
35 /100
Moderate
EPS volatility 198.26%
Beta 0.23x
Profitable years 1

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about BMY
Online

About the company

Bristol-Myers Squibb Company (BMY) is an American pharmaceutical company with a global reach. The company specializes in research, development, and manufacturing of drugs and biological products for the treatment of various diseases. Bristol-Myers Squibb focuses its efforts on the treatment of cancer, cardiovascular diseases, immune disorders, and other serious conditions. The company is known for its innovative medications that bring significant medical benefits to patients. Bristol-Myers Squibb has a wide range of drugs on the market, and its products are distributed worldwide. The company also has an active research program aimed at discovering new drugs and therapeutic approaches. Bristol-Myers Squibb Company (BMY) shares are an attractive choice for investors who follow the pharmaceutical sector and seek investment opportunities in a renowned pharmaceutical company with a focus on innovative treatment methods.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Christopher Boerner

Employees

32,500

Headquarters

Princeton

Upcoming events

29 OCT

Earnings

Upcoming earnings report

46d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.